UK Shareholder Meetings Calendar - Next 7 Days
Wednesday 24 OctoberIndigovisionBeeks FinancialReddePhoto-Me 25 & Smart 26 29 30
Read moreWed, 20th Jul 2016 12:35
Wednesday 24 OctoberIndigovisionBeeks FinancialReddePhoto-Me 25 & Smart 26 29 30
Read moreLONDON (Alliance News) - Immunotherapy firm Scancell Holdings PLC on Tuesday said it is well funded to progress its range of proposed cancer immunotherapies.Scancell is developing for based
Read moreWednesday 19 September KingfisherHalf Year ResultsBabcock InternationalTrading Year Year
Read moreLONDON (Alliance News) - Hygea VCT PLC on Tuesday said net asset value decreased in the first half of its current financial year due to a fall in value of its AIM-listed portfolio in the venture a
Read moreLONDON (Alliance News) - Scancell Holdings PLC on Wednesday said it will secure a European patent for its Moditope immunotherapy platform in mid-June.The cancer treatment developer said the
Read moreLONDON (Alliance News) - Scancell Holdings PLC said Tuesday that it has raised GBP1.2 million through an open offer of 10.1 million shares at a price of 12.0 pence per share.Shares in the a
Read moreLONDON (Alliance News) - Hygea VCT PLC said on Thursday its net present value per share increased in the recent quarter.At March 31, Hygea's NAV per share was 64.4p, up from 63.8p at of
Read moreLONDON (Alliance News) - Immunotherapy developer Scancell Holdings PLC said Wednesday that it raised GBP7.5 million via a placing of 57.4 million shares and a subscription of 5.0 million shares at
Read moreLONDON (Alliance News) - Immunotherapy developer Scancell Holdings PLC said Wednesday that it will raise up to GBP8.0 million via equity issue and also announced a technology shares were down 20%
Read moreLONDON (Alliance News) - Cancer treatment developer Scancell Holdings PLC said on Tuesday it has signed a manufacturing agreement with therapeutic peptide manufacturer the f T
Read more(ShareCast News) - Cancer immunotherapy development company Scancell Holdings announced on Monday its intention to develop its SCIB2 ImmunoBody for the treatment of non-small cell lung cancer in combination with a checkpoint inhibitor. The AIM-traded firm's board approved the decision based on the o
Read more(ShareCast News) - Scancell Holdings, a developer of novel immunotherapies for the treatment of cancer, has reported a third consecutive full year loss due to the costs involved in its expansion in the US. The firm has seen a 3% increase in its operating loss over the last three years. The loss was
Read more